Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ascendis Pharma A/S total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ascendis Pharma A/S's total debt was €384.64M at Jun 30, 2026. For fiscal 2025 it was €814.65M, down 1.0% from the year before. The highest annual figure on record is €823.29M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €814.65M | -1.0% |
| FY2024 | Dec 31, 2024 | €823.29M | +30.7% |
| FY2023 | Dec 31, 2023 | €630.09M | +27.4% |
| FY2022 | Dec 31, 2022 | €494.59M | +371.2% |
| FY2021 | Dec 31, 2021 | €104.96M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €384.64M | -48.6% |
| Q1 FY2026 | Mar 31, 2026 | €834.28M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | €814.65M | -1.0% |
| Q3 FY2025 | Sep 30, 2025 | €757.61M | -0.4% |
| Q2 FY2025 | Jun 30, 2025 | €748.26M | +14.9% |
| Q1 FY2025 | Mar 31, 2025 | €806.87M | +23.3% |
| Q4 FY2024 | Dec 31, 2024 | €823.29M | +30.7% |
| Q3 FY2024 | Sep 30, 2024 | €760.99M | +35.6% |
| Q2 FY2024 | Jun 30, 2024 | €651.24M | +28.7% |
| Q1 FY2024 | Mar 31, 2024 | €654.61M | +29.5% |
| Q4 FY2023 | Dec 31, 2023 | €630.09M | +27.4% |
| Q3 FY2023 | Sep 30, 2023 | €561.31M | +1.5% |
| Q2 FY2023 | Jun 30, 2023 | €505.94M | -1.2% |
| Q1 FY2023 | Mar 31, 2023 | €505.38M | +6.7% |
| Q4 FY2022 | Dec 31, 2022 | €494.59M | +371.2% |
| Q3 FY2022 | Sep 30, 2022 | €553.24M | – |
| Q2 FY2022 | Jun 30, 2022 | €512.21M | – |
| Q1 FY2022 | Mar 31, 2022 | €473.66M | – |
| Q4 FY2021 | Dec 31, 2021 | €104.96M | – |
See a number that looks wrong?